TY - JOUR
T1 - Novel clinical features of glycine receptor antibody syndrome
T2 - A series of 17 cases
AU - Piquet, Amanda L.
AU - Khan, Murtaza
AU - Warner, Judith E.A.
AU - Wicklund, Matthew P.
AU - Bennett, Jeffrey L.
AU - Leehey, Maureen A.
AU - Seeberger, Lauren
AU - Schreiner, Teri L.
AU - Mateo Paz Soldan, M.
AU - Clardy, Stacey L.
N1 - Publisher Copyright:
© 2019 American Academy of Neurology.
PY - 2019/9/1
Y1 - 2019/9/1
N2 - ObjectiveTo describe novel clinical features of GlyRα1-IgG-positive patients.MethodsPatients with a positive serum GlyRα1-IgG were identified during a 2-year period from July 2016 to December 2018 at 2 academic centers and followed prospectively. All patients in this series were evaluated in the Neuroimmunology and Autoimmune Neurology clinics at the University of Utah or the University of Colorado.ResultsThirteen of 17 patients had phenotypes more typically associated with glutamic acid decarboxylase (GAD65) antibody syndromes, consisting of stiff-person syndrome (SPS) with parkinsonism or cerebellar signs. One patient with parkinsonism had a presentation similar to rapidly progressive multiple system atrophy with severe dysautonomia. Ten of 17 patients had various visual symptoms including visual snow, spider web-like images forming shapes and 3-dimensional images, palinopsia, photophobia, visual hallucinations, synesthesia, and intermittent diplopia. Three of 17 patients presented with primarily autoimmune epilepsy accompanied by psychiatric symptoms.ConclusionsClinicians should consider testing for GlyR antibodies in GAD65 antibody-negative or low-positive GAD65 antibody patients with SPS-like presentations, especially in the setting of atypical features such as visual disturbances, parkinsonism, or epilepsy.
AB - ObjectiveTo describe novel clinical features of GlyRα1-IgG-positive patients.MethodsPatients with a positive serum GlyRα1-IgG were identified during a 2-year period from July 2016 to December 2018 at 2 academic centers and followed prospectively. All patients in this series were evaluated in the Neuroimmunology and Autoimmune Neurology clinics at the University of Utah or the University of Colorado.ResultsThirteen of 17 patients had phenotypes more typically associated with glutamic acid decarboxylase (GAD65) antibody syndromes, consisting of stiff-person syndrome (SPS) with parkinsonism or cerebellar signs. One patient with parkinsonism had a presentation similar to rapidly progressive multiple system atrophy with severe dysautonomia. Ten of 17 patients had various visual symptoms including visual snow, spider web-like images forming shapes and 3-dimensional images, palinopsia, photophobia, visual hallucinations, synesthesia, and intermittent diplopia. Three of 17 patients presented with primarily autoimmune epilepsy accompanied by psychiatric symptoms.ConclusionsClinicians should consider testing for GlyR antibodies in GAD65 antibody-negative or low-positive GAD65 antibody patients with SPS-like presentations, especially in the setting of atypical features such as visual disturbances, parkinsonism, or epilepsy.
UR - http://www.scopus.com/inward/record.url?scp=85073327735&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073327735&partnerID=8YFLogxK
U2 - 10.1212/NXI.0000000000000592
DO - 10.1212/NXI.0000000000000592
M3 - Article
C2 - 31355325
AN - SCOPUS:85073327735
SN - 2332-7812
VL - 6
JO - Neurology: Neuroimmunology and NeuroInflammation
JF - Neurology: Neuroimmunology and NeuroInflammation
IS - 5
ER -